These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26372321)

  • 41. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
    Ishibashi Y; Matsui T; Yamagishi SI
    Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Empagliflozin: A Review in Type 2 Diabetes.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
    Thomas MC; Jandeleit-Dahm K; Bonnet F
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
    Prázný M; Slíva J
    Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors.
    Mintz ML
    J Fam Pract; 2016 Dec; 65(12 Suppl):. PubMed ID: 28149983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
    Ito H; Shinozaki M; Nishio S; Abe M
    Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
    Teo YH; Chia AZQ; Teo YN; Chong EY; Syn NL; Cheong JYA; Ong HT; Wee CF; Ting AZH; Tan JTA; Li TYW; Kong WKF; Lee CH; Chan MY; Wong RCC; Yeo TC; Chai P; Sia CH
    J Hypertens; 2022 Dec; 40(12):2353-2372. PubMed ID: 36018229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Weight in Type 2 Diabetes Mellitus and Therapeutic Regimen Recommendation.
    Wang DD; Mao YZ; Yang Y; Wang TY; Zhu P; He SM; Chen X
    J Diabetes Res; 2022; 2022():4491900. PubMed ID: 35342769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Rahman W; Solinsky PJ; Munir KM; Lamos EM
    Expert Opin Pharmacother; 2019 Feb; 20(2):151-161. PubMed ID: 30412008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives.
    Maccari R; Ottanà R
    J Med Chem; 2022 Aug; 65(16):10848-10881. PubMed ID: 35924548
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.
    Baker WL; Smyth LR; Riche DM; Bourret EM; Chamberlin KW; White WB
    J Am Soc Hypertens; 2014 Apr; 8(4):262-75.e9. PubMed ID: 24602971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure.
    Riggs K; Ali H; Taegtmeyer H; Gutierrez AD
    Metab Syndr Relat Disord; 2015 Sep; 13(7):292-7. PubMed ID: 26125313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
    Derosa G; Maffioli P
    Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions.
    Pantelidis P; Kalliakmanis A; Mitas C; Sideris M; Grassos C; Pittaras A; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):86-93. PubMed ID: 29412123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.